Breaking News Instant updates and real-time market news.

MYL

Mylan

$31.36

-0.31 (-0.98%)

06:35
11/06/18
11/06
06:35
11/06/18
06:35

Mylan target raised to $39 on 'comforting' Q3 results at Mizuho

Mylan reported "comforting" Q3 results with $300M in high margin new product sales and reiterated its 2018 guidance, Mizuho analyst Irina Koffler tells investors in a post-earnings research note. The analyst raised her price target for the shares to $39 from $37 and reiterates a Neutral rating on the name.

  • 13

    Nov

MYL Mylan
$31.36

-0.31 (-0.98%)

11/06/18
JPMS
11/06/18
NO CHANGE
Target $45
JPMS
Overweight
Mylan Q3 better than feared, recent selloff overdone, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's Q3 results as "better than feared" and a "step in the right direction." While the company's North American business remains under pressure, year-over-year erosion for the business improved from Q2, overall gross margins showed solid year-over-year improvement and Mylan maintained its annual guidance, Schott tells investors in a post-earnings research note. The analyst views the recent weakness in the shares as overdone and keeps an Overweight rating on the name with a $45 price target. Looking beyond near-term challenges, Mylan is one of the better-positioned players in the space with a number of longer-term growth drivers in place, including biosimilars and the pending generic Advair approval, says Schott.
11/01/18
WELS
11/01/18
NO CHANGE
WELS
Market Perform
Fear of missing out helping to push Teva, Mylan higher, says Wells Fargo
Wells Fargo analyst David Maris believes Teva (TEVA) shares are bouncing back to fair value from recent declines after the company reported Q3 earnings that beat his above consensus estimate and hosted a "surprisingly bullish" quarterly call. He also sees a spillover effect occurring with Mylan (MYL) as the generic sector's advance reinforces buyers' belief that the stocks are undervalued and investors' "fear of missing out" drives increased interest. While Maris acknowledges Ajovy, Austedo, cost cuts and tax management are doing well, he believes much of Teva's business continues to show significant challenges and keeps a Market Perform rating on the shares.
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Sandoz results 'potential warning signal' for generics, says Wells Fargo
Wells Fargo analyst David Maris views this morning's results from Novartis' (NVS) generic unit Sandoz as "another negative datapoint" for generic stocks, notably Teva (TEVA), Mylan (MYL) and Amneal Pharmaceuticals (AMNX). Novartis reported Sandoz net sales of $2.4B, down 4% on constant currency, and noted that sales were pressured by 8% pricing erosion in the quarter, Maris tells investors in a research note. Novartis also highlighted that U.S sales for Sandoz declined 17% due to "industry wide pricing pressure," Maris points out. The analyst views the quarter as a "potential warning signal" for the Q3 earnings season for companies with large U.S. commodity generic exposure. He maintains his caution on "generic industry margin risks."
10/12/18
WELS
10/12/18
NO CHANGE
WELS
Market Perform
Merck returning Lantus biosimilar rights negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris sees a negative read-through for Mylan regarding yesterday's news of Merck Sharp & Dohme Research returning the rights to biosimilar Lantus to Samsung Bioepis. While some view this as a positive, as there will likely be one fewer competitor in the market if Mylan-Biocon make it to the U.S. market, that is a "simplistic and optimistic" take, Maris tells investors in a research note. The more important factor to consider is the "why" Merck dropped out, rather than the number of competitors, the analyst writes. He believes Merck returned the rights to Samsung Bioepis due to the deteriorating pricing environment and pricing outlook for insulin and Lantus biosimilars. Lilly's and Sanofi's manufacturing capacity, along with aggressive discounting, has created a "severe pricing environment," Maris contends. He believes that if Samsung Bioepis and Merck can't make the economics work, than one should be skeptical of Mylan and Biocon having substantial success. Maris has a Market Perform rating on Mylan shares.

TODAY'S FREE FLY STORIES

NCR

NCR Corp.

$28.90

0.58 (2.05%)

16:06
02/22/19
02/22
16:06
02/22/19
16:06
Hot Stocks
NCR acquires reseller BEC, terms not disclosed »

NCR Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

TAHO

Tahoe Resources

$3.67

(0.00%)

16:00
02/22/19
02/22
16:00
02/22/19
16:00
Hot Stocks
Breaking Hot Stocks news story on Tahoe Resources »

Tahoe Resources trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$278.71

1.28 (0.46%)

, SPX

S&P 500

$0.00

(0.00%)

15:57
02/22/19
02/22
15:57
02/22/19
15:57
Periodicals
Special Counsel Mueller will not release his report next week, NBC reports »

Contrary to press…

SPY

SPDR S&P 500 ETF Trust

$278.71

1.28 (0.46%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$172.39

1.27 (0.74%)

15:55
02/22/19
02/22
15:55
02/22/19
15:55
Periodicals
Apple to shutter stores in Eastern District of Texas, MacRumors reports »

Apple intends to shutter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

DPLO

Diplomat Pharmacy

$5.67

-7.79 (-57.88%)

15:54
02/22/19
02/22
15:54
02/22/19
15:54
Downgrade
Diplomat Pharmacy rating change  »

Diplomat Pharmacy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 11

    Mar

  • 12

    Mar

LIN

Linde plc

$173.06

1.65 (0.96%)

, LYB

LyondellBasell

$88.93

0.42 (0.47%)

15:51
02/22/19
02/22
15:51
02/22/19
15:51
Hot Stocks
FTC approves Linde's application for sale of plant to LyondellBasell »

The Federal Trade…

LIN

Linde plc

$173.06

1.65 (0.96%)

LYB

LyondellBasell

$88.93

0.42 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

MGEE

MGE Energy

$66.40

0.42 (0.64%)

15:50
02/22/19
02/22
15:50
02/22/19
15:50
Earnings
MGE Energy reports Q4 EPS 47c vs. $1.04 last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$4.91

-4.05 (-45.20%)

15:50
02/22/19
02/22
15:50
02/22/19
15:50
Options
44% dive in shares motivates interest in KKaryopharm far upside calls »

44% dive in shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

NESR

National Energy Services

$8.75

0.005 (0.06%)

15:48
02/22/19
02/22
15:48
02/22/19
15:48
Syndicate
Breaking Syndicate news story on National Energy Services »

National Energy Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

NIO

NIO Inc.

$7.97

0.355 (4.66%)

15:44
02/22/19
02/22
15:44
02/22/19
15:44
Periodicals
CBS teases upcoming 60 Minutes feature on NIO Inc. »

The 60 Minutes report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

BRK.A

Berkshire Hathaway

$302,770.46

-5154.54 (-1.67%)

, BRK.B

Berkshire Hathaway

$201.90

-3.41 (-1.66%)

15:39
02/22/19
02/22
15:39
02/22/19
15:39
Periodicals
Berkshire Hathaway in advanced talks to sell Applied Underwriters, Reuters says »

Berkshire Hathaway is in…

BRK.A

Berkshire Hathaway

$302,770.46

-5154.54 (-1.67%)

BRK.B

Berkshire Hathaway

$201.90

-3.41 (-1.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTW

WW

$29.34

0.27 (0.93%)

15:35
02/22/19
02/22
15:35
02/22/19
15:35
Options
Weight Watchers put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

15:35
02/22/19
02/22
15:35
02/22/19
15:35
General news
U.S. Treasury Market Summary »

U.S. Treasury Market…

15:28
02/22/19
02/22
15:28
02/22/19
15:28
Conference/Events
House Financial Services Committee to hold a hearing »

The Committee holds a…

IWM

iShares Trust Russell 2000 Index Fund

$157.79

1 (0.64%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:22
02/22/19
02/22
15:22
02/22/19
15:22
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

For the holiday-shortened…

IWM

iShares Trust Russell 2000 Index Fund

$157.79

1 (0.64%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$55.68

0.14 (0.25%)

, XLE

Energy Select Sector SPDR

$65.66

0.1 (0.15%)

15:22
02/22/19
02/22
15:22
02/22/19
15:22
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

At time of writing the…

XLB

S&P Select Materials SPDR

$55.68

0.14 (0.25%)

XLE

Energy Select Sector SPDR

$65.66

0.1 (0.15%)

XLF

Financial Select Sector

$26.43

-0.085 (-0.32%)

XLI

Industrial Select Sector SPDR

$75.89

0.19 (0.25%)

XLY

Consumer Discretionary Sector SPDR

$110.81

0.31 (0.28%)

XLV

Health Care Select Sector SPDR

$92.29

0.59 (0.64%)

XLK

Technology Select Sector SPDR

$70.39

0.64 (0.92%)

SPY

SPDR S&P 500 ETF Trust

$278.35

0.92 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:21
02/22/19
02/22
15:21
02/22/19
15:21
Conference/Events
House Appropriations Committee to hold a hearing »

The Subcommittee on…

RF

Regions Financial

$16.16

-0.085 (-0.52%)

15:20
02/22/19
02/22
15:20
02/22/19
15:20
Options
Call spreads in Regions Financial as bullish positions are adjusted »

Call spreads in Regions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
02/22/19
02/22
15:17
02/22/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
02/22/19
02/22
15:16
02/22/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UA

Under Armour

$19.57

0.16 (0.82%)

15:15
02/22/19
02/22
15:15
02/22/19
15:15
Options
Under Armour put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

15:15
02/22/19
02/22
15:15
02/22/19
15:15
General news
Treasury Action: Treasuries have been underpinned all day »

Treasury Action:…

ABBV

AbbVie

$79.47

0.71 (0.90%)

, AZN

AstraZeneca

$40.78

0.345 (0.85%)

15:14
02/22/19
02/22
15:14
02/22/19
15:14
Conference/Events
Senate Finance Committee to hold a hearing »

The Committee holds a…

ABBV

AbbVie

$79.47

0.71 (0.90%)

AZN

AstraZeneca

$40.78

0.345 (0.85%)

BMY

Bristol-Myers

$50.75

0.6 (1.20%)

JNJ

Johnson & Johnson

$136.22

0.82 (0.61%)

MRK

Merck

$80.39

0.57 (0.71%)

PFE

Pfizer

$42.91

0.77 (1.83%)

SNY

Sanofi

$41.10

-0.23 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

  • 17

    Jun

MGA

Magna

$54.61

2.015 (3.83%)

15:04
02/22/19
02/22
15:04
02/22/19
15:04
Downgrade
Magna rating change  »

Magna downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

LTRPA

Liberty TripAdvisor

$16.20

0.31 (1.95%)

15:04
02/22/19
02/22
15:04
02/22/19
15:04
Options
Liberty TripAdvisor options imply 4.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.